Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients

NCT01240447 | Completed Phase 2

• 2 other identifiers: AR-RACO-02-08ISRCTN47153584
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to evaluate safety and immunogenicity of racotumomab in patients with advanced Non-small Cell Lung Cancer (NSCLC), in concomitance with chemotherapy (docetaxel) when a second-line therapy is indicated. The study will also compare survival and progression free survival on both study arms.

Conditions

Advanced Non-small Cell Lung Cancer

Keywords

NSCLC; lung cancer, small-cell; advanced lung cancer

Outcome Measures

Primary Outcomes (37)

• Number of Participants with Adverse events as a measure of safety and tolerability

  Safety will be evaluated at each study visit according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and will include physical examination with vital signs, performance status as per the Eastern Cooperative Oncology Group scale(ECOG scale), laboratory tests and clinical history.

  Until death, on average during 17 months

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Baseline

• Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.

  Baseline

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Baseline

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Baseline

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Baseline

• Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.

  Month 2

• Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.

  Month 4

• Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.

  Month 8

• Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.

  Month 12

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Baseline

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Month 2

• Measurement of pro-inflammatory and anti-inflammatory cytokines.

  Baseline

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Month 2

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Month 8

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Month 4

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Month 12

• Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside

  Every 4 months (after the first year, on average during 17 months)

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Month 2

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Month 12

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Every 4 months (after the first year, on average during 17 months)

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Month 4

• Evaluation of the reactivity if the antibodies against X63 tumor line

  Month 8

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Month 4

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Month 8

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Month 12

• Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)

  Every 4 months (after the first year, on average during 17 months)

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Month 2

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Month 4

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Month 8

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Month 12

• Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.

  Every 4 months (after the first year, on average during 17 months)

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Month 2

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Month 4

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Month 8

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Month 12

• Measurement of pro-inflammatory and anti-inflammatory cytokines

  Every 4 months (after the first year, on average during 17 months)

Secondary Outcomes (2)

• Survival

  Until date of death or last censored observation

• Progression free survival

  Until first progression of disease

Study Arms (2)

Best support treatment

OTHER

Other: Best support treatment

Racotumomab vaccine

EXPERIMENTAL

Biological: racotumomab

Interventions

racotumomab BIOLOGICAL

Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.

Also known as: 1E10

Racotumomab vaccine

Best support treatment OTHER

Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.

Best support treatment

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient (aged over 21 years, either sex) can comply with the protocol and scheduled appointments and sign voluntarily the informed consent form
• Diagnosis of Non-small cell lung cancer (NSCLC) stages IIIA (surgically unresectable), IIIB or IV, according to the TNM classification (Tumor-Nodes-Metastases) version 6a, confirmed by cytology or histology, if possible available for determination of ganglioside expression
• Patients may enter the study if they have accomplished an objective response (complete response or partial response) or disease stabilisation (by Response Evaluation Criteria In Solid Tumours \[RECIST\]) after completion of standard onco-specific treatment. In all cases, response should be documented.
• For stage IIIA and IIIB without pleural effusion ("dry IIIB") standard treatment is considered as follows: 2 - 4 cycles of platinum-based chemotherapy and/or radiotherapy with curative intent in accordance with National Comprehensive Cancer Network (NCCN) guidelines For stage IIIB with pleural effusion ("wet IIIB") and stage IV standard treatment is considered as follows: 4 - 6 cycles of chemotherapy based on platinum. In case of pleural or pericardial effusion requiring local treatment, it will be provided prior to study entry.
• The subject is male or female, aged greater than or equal to 21 years
• Performance status (Eastern Cooperative Oncology Group \[ECOG\]) less than or equal to 1
• Acceptable organ functionality as defined by the following parameters:
• Electrocardiogram (ECG) without significant abnormalities, performed within 14 days prior to admission
• Haemoglobin greater than or equal to 90 g/L
• Total leukocyte count greater than or equal to 3.0 x 10\^9/L
• Absolute neutrophil count greater than or equal to 1.5 x 10\^9/L
• Total bilirubin less than or equal to 1.5 times upper limit of normal or twice the limit normal than in case liver metastases are present
• Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5 times upper limit of normal (less than or equal to five times the normal maximum in case liver metastases are present)
• Creatinine less than or equal to 2 mg/dL
• Life expectancy of at least four months

You may not qualify if:

• Patient is pregnant or breastfeeding
• Hypersensitivity to any component of the formulation
• Patients of childbearing potential of either sex who are not using an adequate method of contraception during treatment to avoid pregnancy (own or of partner). For females: intrauterine devices, hormonal contraceptives, barrier methods or sterilisation. For males: vasectomy or condoms with spermicide.
• Patients receiving or having received other investigational drugs 30 days prior to study entry
• History of autoimmune diseases
• Decompensated chronic diseases
• Acute allergic disorders or history of severe allergic reactions
• Known brain metastases uncontrolled with surgery and/or radiation therapy or under current corticosteroid therapy
• History of inflammatory or demyelinating disease of the central or peripheral nervous system
• Uncontrolled intercurrent illnesses, including active infection, symptomatic congestive heart failure, unstable angina or cardiac arrhythmia and psychiatric diseases implying patient incompetence
• Other malignancies, with the exception of basal cell carcinoma, in situ cervical carcinoma, incidental prostate cancer (T1a, Gleason less than or equal to 6, prostate specific antigen \[PSA\] less than 0.5 ng/ml), tumour or any other tumour adequately treated and with a disease-free period greater than or equal to 5 years
• Chronic treatment with systemic corticosteroids at doses greater than 0.5 mg/kg/day or a maximum of 40 mg/day of prednisone or equivalent
• The subject has a history of drug abuse (illicit drugs) or alcohol abuse (defined as regular or periodic ingestion of more than four drinks a day) in the last 2 years
• Positive serology for hepatitis B, C or known human immunodeficiency virus (HIV) infection
• Uncontrolled hypercalcaemia greater than or equal to 2.9 mmol/L (or grade greater than 1 according to the Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0)

Sponsors & Collaborators

• Laboratorio Elea Phoenix S.A.: lead

Study Sites (1)

Instituto de Oncología "Angel H. Roffo"

Buenos Aires, Buenos Aires, C1417DTB, Argentina

Location

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

racotumomab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Gabriela Cinat, MD

  Instituto de Oncología "Angel H. Roffo"

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2010
• First Posted: November 15, 2010
• Study Start: September 1, 2009
• Primary Completion: August 1, 2012
• Study Completion: June 1, 2014
• Last Updated: July 10, 2014

Record last verified: 2014-07

Locations

AR (1)